Alkylenediammonium diclavulanate derivatives, a process for the

Abstract

A novel process for the preparation of calvulanic acid and pharmaceutically acceptable salt thereof, such as potassium clavulanate, is described. According to the novel process, crude clavulanic acid, which is present in the form of an extract in an organic solvent, such as ethyl acetate, the extract having been obtained in known manner upon fermentation with a calvulanic acid producing microorganism, is reacted with substituted alkylenediamines of the formula II ##STR1## wherein the substituents R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 and n have the meanings as defined in claim 1, e.g. with N,N'-diisopropylethylenediamine, to the novel alkylenediammonium diclavulanates of the formula I ##STR2## wherein the substituents R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 and n have the meanings as defined in claim 1, e.g. to N,N'-diisopropylethylenediammonium diclavulanate. The obtained compounds of the formula I are optionally isolated and converted with alkali alkanoates, such as potassium 2-ethylhexanoate in isopropanol, to potassium clavulanate. Because of their high inhibitory action against beta-lactamases and because of a significant synergistic action in combination with the beta-lactam antibiotics from the group of penicillins and cephalosporins, clavulanic acid and pharmaceutically acceptable salts thereof are valuable compounds for the preparation of galenic compositions, which are active in the treatment of infectious diseases induced by numerous grampositive and gram-negative microorganisms.